NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD
5.36
+0.33 (+6.56%)
The current stock price of ALT is 5.36 USD. In the past month the price increased by 46.05%. In the past year, price decreased by -25.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.31 | 332.73B | ||
AMGN | AMGEN INC | 13.29 | 148.31B | ||
GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
NTRA | NATERA INC | N/A | 21.77B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
BIIB | BIOGEN INC | 7.41 | 17.17B |
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
ALTIMMUNE INC
910 Clopper Road, Suite 201S
Gaithersburg MARYLAND 20878 US
CEO: Vipin K. Garg
Employees: 59
Phone: 12406541450
The current stock price of ALT is 5.36 USD. The price increased by 6.56% in the last trading session.
The exchange symbol of ALTIMMUNE INC is ALT and it is listed on the Nasdaq exchange.
ALT stock is listed on the Nasdaq exchange.
12 analysts have analysed ALT and the average price target is 22.29 USD. This implies a price increase of 315.94% is expected in the next year compared to the current price of 5.36. Check the ALTIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALTIMMUNE INC (ALT) has a market capitalization of 412.77M USD. This makes ALT a Small Cap stock.
ALTIMMUNE INC (ALT) currently has 59 employees.
ALTIMMUNE INC (ALT) has a support level at 5.02 and a resistance level at 5.65. Check the full technical report for a detailed analysis of ALT support and resistance levels.
The Revenue of ALTIMMUNE INC (ALT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALT does not pay a dividend.
ALTIMMUNE INC (ALT) will report earnings on 2025-05-08, before the market open.
ALTIMMUNE INC (ALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
The outstanding short interest for ALTIMMUNE INC (ALT) is 29.37% of its float. Check the ownership tab for more information on the ALT short interest.
ChartMill assigns a technical rating of 1 / 10 to ALT. When comparing the yearly performance of all stocks, ALT is a bad performer in the overall market: 79.45% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ALT. While ALT has a great health rating, there are worries on its profitability.
Over the last trailing twelve months ALT reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS increased by 6.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -68.24% | ||
ROE | -76.97% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to ALT. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -10.3% and a revenue growth -100% for ALT